Solid Lipid Nanoparticles Enhancing the Leishmanicidal Activity of Delamanid
Pharmaceutics · 27.12.2023 · 16 (1) · 41
DOI: 10.3390/pharmaceutics16010041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 27.12.2023. Verfasst von Javier Santamaría-Aguirre und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Biología Molecular, Universidad de Cantabria, 39011 Santander, Spain. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Estatal de Investigación, European Regional Development Fund, Instituto de Investigación Marqués de Valdecilla.
Abstract (Originalsprache)
Leishmaniasis, a zoonotic parasitic disease transmitted by infected sandflies, impacts nearly 1 million people yearly and is endemic in many countries across Asia, Africa, the Americas, and the Mediterranean; despite this, it remains a neglected disease with limited effective treatments, particularly in impoverished communities with limited access to healthcare. This study aims to repurpose approved drugs for an affordable leishmaniasis treatment. After the screening of potential drug candidates by reviewing databases and utilizing molecular docking analysis, delamanid was chosen to be incorporated into solid lipid nanoparticles (SLNPs). Both in cellulo and in vivo tests confirmed the successful payload release within macrophages and through the epidermis following topical application on murine skin. The evaluation of macrophages infected with L. infantum amastigotes showed that the encapsulated delamanid exhibited greater leishmanicidal activity compared with the free drug. The process of encapsulating delamanid in SLNPs, as demonstrated in this study, places a strong emphasis on employing minimal technology, ensuring energy efficiency, cost-effectiveness, and reproducibility. It enables consistent, low-cost production of nanomedicines, even on a small scale, offering a promising step toward more accessible and effective leishmaniasis treatments.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departamento de Biología Molecular, Universidad de Cantabria, 39011 Santander, Spain.
- Grupo de Nanomedicina, Instituto Valdecilla-IDIVAL, 39011 Santander, Spain.
- Grupo de Investigación en Biodiversidad, Zoonosis y Salud Pública (GIBCIZ), Instituto de Investigación en Zoonosis (CIZ), Facultad de Ciencias Químicas (FCQ), Universidad Central del Ecuador, Quito 170521, Ecuador.
- Facultad de Ciencias Químicas (FCQ), Universidad Central del Ecuador, Quito 170521, Ecuador.
- Departamento de Ingeniería Química, Instituto de Simulación Computacional (ISC-USFQ), Universidad San Francisco de Quito USFQ, Quito 170157, Ecuador.
- Grupo ICPVet, Departamento Sanidad Animal, Universidad Complutense de Madrid, 28040 Madrid, Spain.
ORCID-Profile: Javier Santamaría-Aguirre, Miguel A Méndez, Ana Poveda, Javier Carrión, Mónica L Fanarraga
Förderung
- Agencia Estatal de Investigación
- European Regional Development Fund
- Instituto de Investigación Marqués de Valdecilla
- MICIN/AEI/ 1013039/501100011033
- AEI and European Regional Development Fund, “Investing in your future”
- “One Health drugs against parasitic vector-borne diseases in Europe and beyond (OneHealthdrugs)” COST action
- Spanish Nanomedicine network
- IDIVAL
Zitieren
APA
Santamaría-Aguirre, J., Jacho, D., Méndez, M. A., Poveda, A., Carrión, J., & Fanarraga, M. L. (2023). Solid Lipid Nanoparticles Enhancing the Leishmanicidal Activity of Delamanid. Pharmaceutics, 16(1), 41. https://doi.org/10.3390/pharmaceutics16010041
Vancouver
Santamaría-Aguirre J, Jacho D, Méndez MA, Poveda A, Carrión J, Fanarraga ML. Solid Lipid Nanoparticles Enhancing the Leishmanicidal Activity of Delamanid. Pharmaceutics. 2023;16(1):41. doi:10.3390/pharmaceutics16010041
BibTeX
@article{SantamaraAguirre2023,
author = {Santamaría-Aguirre, Javier and Jacho, Daniela and Méndez, Miguel A and Poveda, Ana and Carrión, Javier and Fanarraga, Mónica L},
title = {Solid Lipid Nanoparticles Enhancing the Leishmanicidal Activity of Delamanid},
journal = {Pharmaceutics},
year = {2023},
volume = {16},
number = {1},
pages = {41},
doi = {10.3390/pharmaceutics16010041}
}
EUVIMED